Scribano, M.D., Alessandro Armuzzi, M.D., Ph.D., Flavio Caprioli, M.D., Ph.D., Giacomo C. Sturniolo, M.D., Francesca Rogai, M.D., Ph.D., Maurizio Vecchi, M.D., Raja Atreya, M.D., Ph.D., Fabrizio Bossa, M.D., Sara Onali, M.D., Ph.D., Maria Fichera, M.D., Gino R. Corazza, M.D., Livia Biancone, M.D., Ph.D., Vincenzo Savarino, M.D., Roberta Pica, M.D., Ambrogio Orlando, M.D., and Francesco Pallone, M.D. It generally affects old females and develops when the cells of the ovary start to grow in an instant and uncontrollable way. There are numerous of symptoms connected with ovarian cancer including a bloated stomach, irregular periods and abdominal pain.And then Gilead Sciences was off to the races. The business said it sold $2.27 billion well worth of Sovaldi in the one fourth that ended March 31. $2.27 billion! The boffo number beat Wall Road's estimate for the quarter by more than $1 billion . PBS NewsHour: New Hepatitis-C Drug Raises Hope At A Hefty Cost A new drug has a 90 to 100 % potential for curing the Hepatitis-C virus, but costs tens of thousands of dollars for a treatment. The announcement by the manufacturer that it earned more than $2 billion in the year's first quarter raises the relevant issue, who should spend when drugs work highly, but expensive extremely? Hari Sreenivasan reports on the profits, protection and costs .